机构

• 上海药物研究所 [9]
• 合肥物质科学研究院 [2]
• 武汉物理与数学研究所 [1]
• 自动化研究所 [1]

采集方式

• OAI收割 [13]

内容类型

• 期刊论文 [13]

发表日期

• 2023 [1]
• 2022 [1]
• 2021 [1]
• 2020 [2]
• 2019 [1]
• 2018 [3]
• 更多

学科主题

筛选

浏览/检索结果: 共13条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer 期刊论文  OAI收割 SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 卷号: 8, 期号: 1, 页码: 13 作者:  Zhou, Ji;  Zhang, Xu-Chao;  Xue, Shan;  Dai, Mengdi;  Wang, Yueliang   |  收藏  |  浏览/下载：12/0  |  提交时间：2023/10/17 Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements 期刊论文  OAI收割 NPJ PRECISION ONCOLOGY, 2022, 卷号: 6 作者:  Zhang, Yongchang;  Huang, Zhe;  Zeng, Liang;  Zhang, Xiangyu;  Li, Yizhi   |  收藏  |  浏览/下载：42/0  |  提交时间：2022/05/05 A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib 期刊论文  OAI收割 CLINICAL LUNG CANCER, 2021, 卷号: 22 作者:  Chen, Kaiyan;  Zhang, Fanrong;  Pan, Guoqiang;  Sheng, Jiamin;  Ye, Junyi   |  收藏  |  浏览/下载：45/0  |  提交时间：2021/03/15 Crizotinib  MET  Non-small-cell lung cancer  RET  Resistance   SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 7 作者:  Xia, Zong-jun;  Ji, Yin-chun;  Sun, De-qiao;  Peng, Xia;  Gao, Ying-lei   |  收藏  |  浏览/下载：47/0  |  提交时间：2020/12/21 ROS1 kinase  ROS1 inhibitor  SAF-189s  lorlatinib  crizotinib resistance  G2032R mutant  NSCLC   CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study 期刊论文  OAI收割 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10, 页码: 9 作者:  Li, Hailin;  Zhang, Rui;  Wang, Siwen;  Fang, Mengjie;  Zhu, Yongbei   |  收藏  |  浏览/下载：51/0  |  提交时间：2020/04/07 computed tomography  radiomics  non-small-cell lung cancer  tyrosine kinase inhibitor resistance  anaplastic lymphoma kinase   SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met 期刊论文  OAI收割 CANCER SCIENCE, 2019, 页码: 11 作者:  Tong, Mengya;  Gao, Mingzhao;  Xu, Yongping;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：49/0  |  提交时间：2020/07/01 AZD9291  c-Met ADC  c-Met overexpression  resistance  SHR-A1403   Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 152, 页码: 76-86 作者:  Geng, Kaijun;  Liu, Hongchun;  Song, Zilan;  Zhang, Chi;  Zhang, Minmin   |  收藏  |  浏览/下载：146/0  |  提交时间：2019/01/08 Heat shock protein 90 (Hsp90)  Tyrosine kinase ALK  Dual inhibitor  Drug resistance  Antiproliferative activity   Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 144, 页码: 386-397 作者:  Geng, Kaijun;  Xia, Zongjun;  Ji, Yinchun;  Zhang, Ruisi (Ruthy);  Sun, Deqiao   |  收藏  |  浏览/下载：125/0  |  提交时间：2019/01/08 ALK  G1202R mutant  Drug resistance  2,4-Diarylaminopyrimidine  Resorcinol   Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met 期刊论文  OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 卷号: 8, 期号: 8, 页码: 1541-1550 作者:  Wang, Lei;  Gao, Mingzhao;  Tong, Mengya;  Xie, Chengying;  He, Ye   |  收藏  |  浏览/下载：121/0  |  提交时间：2019/01/08 CT-711  ALK  c-Met  crizotinib  antitumor activity  pharmacokinetics   Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones 期刊论文  OAI收割 SCIENTIFIC REPORTS, 2017, 卷号: 7 作者:  Xu, Shan;  Zhou, Yanping;  Geng, Hui;  Song, Dandan;  Tang, Jing   |  收藏  |  浏览/下载：30/0  |  提交时间：2018/11/05